Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | ESR1 | P03372 | 10/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707840 | 1.00 | BLM (0.87) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL9370 | 0.93 | BLM (1.00) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL6231203 | 0.93 | BLM (1.00) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL2496868 | 0.91 | BLM (0.96) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL809597 | 0.91 | BLM (0.96) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL8153893 | 0.90 | BLM (0.70) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL3664191 | 0.90 | BLM (0.93) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL30306312 | 0.88 | BLM (0.67) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL9371 | 0.88 | BLM (0.67) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL7617243 | 0.87 | BLM (0.87) | BLMESR1NR1I2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-109789225-B | DNA monoclonal antibodies targeting checkpoint molecules | 宾夕法尼亚大学理事会 | 2025-05-13 | — | — | CN | disclosed |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240083899-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11897885-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| CN-116981694-A | anti-PD-1 polypeptides and uses thereof | 苏州鑫康合生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116940595-A | anti-TIGIT antibodies and uses thereof | 苏州鑫康合生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230277546-A1 | AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| EP-3590938-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1591441-A1 | CARBOXYLIC ACID COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6930115-B2 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-16 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
| CN-1620285-A | Novel microspheres and process for producing the same | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-05-25 | — | — | CN | disclosed |
| US-20030165576-A1 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | BLM 1808/4885ESR1 2624/4885ESR2 3051/4885 |
| US-11897885-B2 | Purinone derivative hydrochloride | BTK, P2RY1, P2RY13 | BLM 1808/4885ESR1 2624/4885ESR2 3051/4885 |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | BLM 686/4885ESR1 3055/4885ESR2 2375/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | BLM 1544/4885ESR1 1504/4885ESR2 2078/4885 |
| US-20030165576-A1 | Antitumor effect potentiators | RHOT2, ROCK2, CIT | BLM 2426/4885ESR1 4592/4885ESR2 3953/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | BLM 1978/4885ESR1 661/4885ESR2 1319/4885 |
| US-20240083899-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | BLM 1544/4885ESR1 1504/4885ESR2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.